Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations
DarioHealth (NASDAQ: DRIO) has published new research in the Journal of Medical Internet Research demonstrating the effectiveness of their personalized digital health interventions for increasing flu vaccination awareness among diabetes patients. The study analyzed 64,904 members divided into three groups: one receiving monthly flu vaccination messages, another receiving more personalized and frequent messages, and a control group.
The research revealed that the group receiving personalized messaging showed significantly higher awareness of flu-related risks and increased vaccination rates compared to the group receiving standard messages. This pragmatic follow-up study built upon a previous randomized controlled trial, translating initial insights into real-world applications through Dario's diabetes management platform.
DarioHealth (NASDAQ: DRIO) ha pubblicato una nuova ricerca sul Journal of Medical Internet Research che dimostra l'efficacia delle loro interventi digitali personalizzati per aumentare la consapevolezza sulla vaccinazione antinfluenzale tra i pazienti diabetici. Lo studio ha analizzato 64.904 membri suddivisi in tre gruppi: uno che riceveva messaggi mensili sulla vaccinazione antinfluenzale, un altro con messaggi più personalizzati e frequenti, e un gruppo di controllo.
La ricerca ha evidenziato che il gruppo che riceveva messaggi personalizzati mostrava una consapevolezza significativamente maggiore sui rischi legati all'influenza e tassi di vaccinazione più elevati rispetto al gruppo con messaggi standard. Questo studio pragmatico di follow-up si basa su un precedente trial randomizzato controllato, traducendo le prime intuizioni in applicazioni concrete tramite la piattaforma di gestione del diabete di Dario.
DarioHealth (NASDAQ: DRIO) ha publicado una nueva investigación en el Journal of Medical Internet Research que demuestra la efectividad de sus intervenciones digitales personalizadas para aumentar la conciencia sobre la vacunación contra la gripe entre pacientes con diabetes. El estudio analizó a 64,904 miembros divididos en tres grupos: uno que recibía mensajes mensuales sobre la vacunación contra la gripe, otro que recibía mensajes más personalizados y frecuentes, y un grupo de control.
La investigación reveló que el grupo que recibía mensajes personalizados mostró una conciencia significativamente mayor sobre los riesgos relacionados con la gripe y aumentó las tasas de vacunación en comparación con el grupo que recibía mensajes estándar. Este estudio pragmático de seguimiento se basó en un ensayo controlado aleatorio previo, traduciendo las primeras ideas en aplicaciones reales a través de la plataforma de gestión de diabetes de Dario.
DarioHealth(NASDAQ: DRIO)는 Journal of Medical Internet Research에 당뇨병 환자들의 독감 예방접종 인식을 높이기 위한 맞춤형 디지털 건강 개입의 효과를 입증하는 새로운 연구를 발표했습니다. 이 연구는 64,904명의 회원을 세 그룹으로 나누어 분석했으며, 한 그룹은 월별 독감 예방접종 메시지를 받았고, 다른 그룹은 더 개인화되고 빈번한 메시지를 받았으며, 대조군도 포함되었습니다.
연구 결과, 맞춤형 메시지를 받은 그룹이 독감 관련 위험 인식이 크게 높아지고 예방접종률도 표준 메시지를 받은 그룹보다 증가한 것으로 나타났습니다. 이 실용적인 후속 연구는 이전의 무작위 대조 시험을 기반으로 하여 초기 통찰을 Dario의 당뇨병 관리 플랫폼을 통해 실제 적용으로 전환했습니다.
DarioHealth (NASDAQ : DRIO) a publié une nouvelle recherche dans le Journal of Medical Internet Research démontrant l'efficacité de leurs interventions numériques personnalisées en santé pour accroître la sensibilisation à la vaccination contre la grippe chez les patients diabétiques. L'étude a analysé 64 904 membres répartis en trois groupes : un groupe recevant des messages mensuels sur la vaccination contre la grippe, un autre recevant des messages plus personnalisés et fréquents, et un groupe témoin.
La recherche a révélé que le groupe recevant des messages personnalisés présentait une sensibilisation significativement plus élevée aux risques liés à la grippe et un taux de vaccination accru par rapport au groupe recevant des messages standards. Cette étude pragmatique de suivi s'appuie sur un essai contrôlé randomisé antérieur, traduisant les premières conclusions en applications concrètes via la plateforme de gestion du diabète de Dario.
DarioHealth (NASDAQ: DRIO) hat eine neue Studie im Journal of Medical Internet Research veröffentlicht, die die Wirksamkeit ihrer personalisierten digitalen Gesundheitsinterventionen zur Steigerung des Bewusstseins für Grippeimpfungen bei Diabetespatienten zeigt. Die Studie analysierte 64.904 Mitglieder, die in drei Gruppen eingeteilt wurden: eine Gruppe erhielt monatliche Grippeimpfungsnachrichten, eine andere erhielt individuellere und häufigere Nachrichten, und eine Kontrollgruppe.
Die Forschung zeigte, dass die Gruppe mit personalisierten Nachrichten ein deutlich höheres Bewusstsein für grippebezogene Risiken und höhere Impfraten aufwies als die Gruppe mit Standardnachrichten. Diese pragmatische Nachfolgestudie baute auf einer vorherigen randomisierten kontrollierten Studie auf und übertrug erste Erkenntnisse in reale Anwendungen über die Diabetes-Management-Plattform von Dario.
- Study published in a reputable journal (JMIR) validates Dario's digital health solution effectiveness
- Large-scale study with 64,904 members demonstrates platform's capability to handle significant user base
- Personalized messaging showed measurable improvement in vaccination awareness and rates
- Results support Dario's approach to personalized digital health interventions
- None.
New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes
People living with diabetes are at risk of severe complications from the flu, yet low awareness keeps many from receiving an influenza vaccination. To better understand how digital health tools could raise awareness and improve vaccination rates in this population a pragmatic randomized follow-up study was performed using Dario's digital health solution for diabetes management which delivers a highly personalized, whole health approach to help members improve overall health and outcomes. The study also aimed to highlight the effectiveness of personalizing digital interventions to positively impact member engagement and behavior change.
A previous randomized controlled study ("RCT") proved the effectiveness of a nudge intervention to improve vaccination rates, and Dario's study's was designed as a pragmatic follow-up to translate the initial insights into a real-world setting. To accomplish this, the research team leveraged Dario's capabilities around personalization to deliver tailored messaging across a large data set of 64,904 members segmented into three groups: first, a group of members with exposure to a monthly flu vaccination campaign previously proven to impact vaccination rates; second, a group of members receiving an adapted version of the same campaign with more personalized and frequent messages; and third, a control group with no exposure to flu vaccination messages.
The results showcase the power of personalized digital health interventions with the second group demonstrating significantly improved awareness of the risks associated with the flu and higher rates of vaccination than the group receiving the messages previously tested in the RCT.
"At Dario, we're constantly striving to deepen member engagement through personalized, meaningful interventions that drive real outcomes," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "This study highlights how our personalization engine can deliver measurable clinical impact. By helping members better understand their health and take action, such as avoiding severe flu-related complications, we believe that Dario is able to improve both individual well-being and client outcomes."
"Digital health creates powerful opportunities to engage people and change behaviors in meaningful ways. This study adds to the growing body of evidence showing how solutions like Dario can drive real clinical outcomes," said Omar Manejwala, M.D., Chief Medical Officer at Dario. "We believe deeply in the power of personalization to improve health, and we're proud to have our work featured in JMIR—a recognition of the science behind Dario's approach to transforming care through digital innovation."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the deepening member engagement through personalized, meaningful intervention through the Company's platform; the Company's ability to improve both individual well-being and client outcomes through its platform; and that the Company's approach can transform care through digital innovation. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/darios-digital-health-solution-demonstrates-effectiveness-in-new-research-examining-flu-vaccination-awareness-in-high-risk-populations-302449932.html
SOURCE DarioHealth Corp.
FAQ
What were the key findings of DRIO's flu vaccination awareness study?
How many participants were included in DarioHealth's (DRIO) vaccination awareness study?
What journal published DarioHealth's (DRIO) latest research findings?
How does DarioHealth's (DRIO) digital platform improve vaccination rates?
What population did DarioHealth's (DRIO) vaccination study target?
